The article 🌱 Patch AM: What Grand Rapids’ mayor says is coming for your neighborhood in 2026 appeared first on Grand Rapids Patch. Cheers Grand Rapids! We’re back, helping you stay up to date with ...

Eli Lilly on Monday, Dec. 1 slashed prices of its blockbuster weight loss drug Zepbound for consumers who buy the prescription medication directly from the drugmaker. Lilly's price cuts ranged from ...

The world’s largest drugmaker, Eli Lilly & Co., just notched another milestone: it’s the first health-care company to cross the $1 trillion threshold as investors bet big on the drugmaker’s ...

The 150-year-old drugmaker is the first company in health care to hit the milestone. By Rebecca Robbins Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, ...

Silicon Valley’s giants crowd the list of the world’s most valuable companies, but drugmaker Eli Lilly is hot on their heels. The company topped a market capitalization of $1 trillion on Friday, ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. One particular hurdle for some patients, however, has been the price of these products. Medicare so far hasn't ...

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ...

Patients will be able to access Eli Lilly's weight loss drug Zepbound at Walmart pharmacies nationwide through its direct-to-consumer program as soon as next month. The partnership between Eli Lilly ...

Eli Lilly stock (NYSE: LLY) is up 10% this month, a rise driven by strong clinical trial progress. This includes the announcement of positive Phase 3 results in October 2025 for its oral GLP-1 drug, ...

Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, HER2−, high-risk early breast cancer. Seven-year results from the ...

News provided by Eli Lilly and Company Oct 17, 2025, 8:00 AM ET Verzenio is the first contemporary therapy in over two decades to demonstrate a significant overall survival benefit in adjuvant HR+, ...